Applying science to drug discovery.

Area of Science:

• Pharmaceutical Science
• Biochemistry
• Metabolic Research

Background:

• Academic research provides essential training and novel ideas for pharmaceutical drug discovery.
• A strong alliance between academia and industry accelerates therapeutic development and understanding of physiological processes.

Purpose of the Study:

• To illustrate the symbiotic relationship between basic research and pharmaceutical development through industry case studies.
• To highlight advancements in treating angina and diabetes (Type I and Type II) stemming from this collaboration.

Main Methods:

• Case study analysis of drug discovery programs within three pharmaceutical companies.
• Investigation of metabolic pathways, protein structure-function relationships, and recombinant technologies.

Main Results:

• Elucidation of the anti-anginal agent ranolazine's mechanism through a metabolic lens.
• Development of improved therapies for Type I diabetes using insulin knowledge and recombinant approaches.
• Harnessing glucagon-like polypeptide 1 (GLP-1) for Type II diabetes treatment.
• Discovery of novel binding sites on glycogen phosphorylase and glucokinase, advancing metabolic enzyme understanding and Type II diabetes therapies.

Conclusions:

• The integration of academic research significantly enhances drug discovery and therapeutic innovation in the pharmaceutical industry.
• This collaborative approach yields deeper insights into metabolic diseases and leads to more effective patient treatments.